|
 |
levalbuterol HClThis page contains recent news articles, when available, and an overview of levalbuterol HCl but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Sepracor`s currently marketed products in the US include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand ... Reuters Sepracor Announces Second Quarter 2005 Operating Results - Jul 19, 2005 XOPENEX(R) brand levalbuterol HCl - Marketed through Sepracor's sales force, XOPENEX Inhalation Solution is a short-acting bronchodilator indicated for the ... RedOrbit Sepracor Announces Final Settlement of XOPENEX(R) Inhalation … - Jan 5, 2008 In addition to the royalties described above, Breath will pay Sepracor on a cost plus margin basis for supply of the levalbuterol HCl products. ... Ad-Hoc-News - Ad-Hoc-News (Pressemitteilung) SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 MILLION. - Sep 1, 2005 XOPENEX(R) brand levalbuterol HCl - Marketed through Sepracor's sales force, XOPENEX Inhalation Solution is a short-acting bronchodilator indicated for the ... Entrepreneur Sepracor Announces Fourth Quarter and Full Year 2005 Results; … - Jan 31, 2006 XOPENEX(R) brand levalbuterol HCl Inhalation Solution - XOPENEX Inhalation Solution revenues increased by 34 percent in 2005 versus 2004, reaching $428.5 ... RedOrbit Sepracor Announces First Quarter 2005 Operating Results - Apr 25, 2005 XOPENEX(R) brand levalbuterol HCl -- XOPENEX brand levalbuterol HCl Inhalation Solution is marketed through Sepracor's 1250-person sales force. ... RedOrbit Sepracor Announces Third Quarter 2005 Operating Results. - Oct 25, 2005 XOPENEX(R) brand levalbuterol HCl Inhalation Solution - XOPENEX Inhalation Solution is a short-acting bronchodilator indicated for the treatment or ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Sepracor Announces Fourth Quarter and Full Year 2004 … - Jan 27, 2005 XOPENEX(R) brand levalbuterol HCl -- XOPENEX brand levalbuterol HCl inhalation solution is marketed through Sepracor's 1250-person sales force. ... Pay-Per-View - PR Newswire - HighBeam Research Article: SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 … - Sep 1, 2005 ...levalbuterol HCl, Sepracor) A single-isomer version of albuterol for treating or preventing bronchospasm in people 12 years of age and older with reversible ... Pay-Per-View - Biotech Financial Reports - HighBeam Research Business & Finance; Science-based pharmaceutical company reports Q4, … - Feb 21, 2005 Xopenex brand levalbuterol HCl inhalation solution is marketed through Sepracor. Xopenex is a short-acting bronchodilator indicated for the treatment or ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Business & Finance; Science-based pharmaceutical company reports Q4, … - Feb 27, 2005 Xopenex brand levalbuterol HCl inhalation solution is marketed through Sepracor. Xopenex is a short-acting bronchodilator indicated for the treatment or ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Business & Finance; Science-based pharmaceutical company reports Q4, … - Feb 25, 2005 Xopenex brand levalbuterol HCl inhalation solution is marketed through Sepracor. Xopenex is a short-acting bronchodilator indicated for the treatment or ... Pay-Per-View - Drug Week - Factiva, from Dow Jones SEPR - Sepracor Inc Company Profile - CNNMoney.com - Dec 12, 2008 ...for the treatment of insomnia in adults XOPENEX(r) 'levalbuterol HCl' Inhalation Solution, a shortacting bronchodilator, for the treatment or prevention ... CNNMoney.com Press Release: Sepracor Announces First Quarter 2005 Operating … - Apr 25, 2005 XOPENEX(R) brand levalbuterol HCl -- XOPENEX brand levalbuterol HCl Inhalation Solution is marketed through Sepracor's 1250-person sales force. ... Pay-Per-View - PR Newswire - HighBeam Research Rebounding Amgen Trumps Q2 Estimates Despite Profit Decline - Jul 30, 2008 Sales of insomnia drug Lunesta (eszopiclone) were $148.1 million, while sales of Xopenex (levalbuterol HCl) for treatment or prevention of bronchospasm in ... BioWorld Online - BioWorld Online Sepracor Inc. Announces Third Quarter 2007 Results and Planned … - Oct 30, 2007 XOPENEX([R]) brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in ... Free with registration - Business Wire - AccessMyLibrary.com Sepracor Inc. And Eisai Co. Ltd. Announce Partnership for Development... - Jul 27, 2007 Currently marketed products include LUNESTA brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol tartrate ... RedOrbit XOPENEX(R) Brand of Levalbuterol Data to Be Presented at American … - Oct 18, 2006 ...for XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol and XOPENEX(R) (levalbuterol HCl) Inhalation Solution will be presented at CHEST 2006, ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Inc. Reports Second Quarter 2008 Results - Jul 29, 2008 XOPENEX(R) brand levalbuterol HCl Inhalation Solution, a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients ... Genetic Engineering News - Genetic Engineering News (press release) Data for XOPENEX(R) Brand of Levalbuterol Presented at American … - Oct 23, 2006 ...data from studies of XOPENEX HFA([R]) (levalbuterol tartrate) Inhalation Aerosol and XOPENEX([R]) (levalbuterol HCl) Inhalation Solution at CHEST 2006, ... Free with registration - Business Wire - AccessMyLibrary.com Sepracor Inc. Announces Second Quarter 2007 Results and Significant … - Jul 27, 2007 XOPENEX([R]) brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in ... Free with registration - Business Wire - AccessMyLibrary.com Sepracor Issues Statement Regarding CMS Medicare Part B … - Jun 18, 2007 ...bundled, third quarter 2007 payment amount for XOPENEX(R) (levalbuterol HCl) Inhalation Solution and generic albuterol inhalation solution products. ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for … - Jan 2, 2008 Currently marketed products include LUNESTA brand eszopiclone, XOPENEX([R]) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA([R]) brand levalbuterol ... Free with registration - Business Wire - AccessMyLibrary.com Sepracor Announces Third Quarter 2006 Operating Results - Oct 26, 2006 ...of which revenues from pharmaceutical product sales were $193.4 million ($92.5 million for sales of XOPENEX brand levalbuterol HCl Inhalation Solution ... Genetic Engineering News - Genetic Engineering News (press release) BROVANA(TM) Inhalation Solution Now Available by Prescription for … - Apr 11, 2007 Sepracor's sales force has marketed XOPENEX brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or ... Free with registration - Business Wire - AccessMyLibrary.com Medicaid Price Mistakes Could Cost $100M - Jan 30, 2008 The firm markets Xopenex (levalbuterol HCl), a short-acting bronchodilator indicated for the treatment or prevention of bronchospasm in patients 6 years or ... BioWorld Online - BioWorld Online SEPRACORE REPORTS NET INCOME OF $11.3 MIL FOR 2ND QTR … - Sep 1, 2006 XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Marketed through Sepracor's sales force, XOPENEX Inhalation Solution is a short-acting ... Entrepreneur Sepracor Announces First Quarter 2007 Results - Apr 24, 2007 ...of which revenues from Sepracor's pharmaceutical product sales were approximately $321.3 million (XOPENEX(R) brand levalbuterol HCl Inhalation Solution ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Announces Phase III Data for Eslicarbazepine Acetate … - Jun 19, 2008 Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... RedOrbit Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development... - Jul 26, 2007 Currently marketed products include LUNESTA brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Insomnia - EMEA Issues Positive Opinion For LUNIVIA(R) (Eszopiclone) ... - Oct 26, 2008 Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol ... Medical News Today - Medical News Today (press release) PARI's TREK and LC Plus Deliver Sepracor's New COPD Medication. - Oct 12, 2006 ...(levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); and XOPENEX(R) (levalbuterol HCl) Inhalation Solution. ... $4.95 - PR Newswire - ECNext Sepracor Sues Barr Over Generic Xopenex Plans - Jul 25, 2007 Barr said it submitted its ANDA containing Paragraph IV certification seeking to market generic Xopenex (levalbuterol HCl) in March, and the FDA accepted ... FDA news - FDA news (subscription) Sepracor Announces Full Support of PhRMA's Revised Code on … - Jul 14, 2008 Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Announces First Quarter 2006 Results. - Apr 25, 2006 XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Indicated for treatment or prevention of bronchospasm in patients with reversible obstructive airway. $4.95 - Business Wire - ECNext FDA Approves Xopenex HFA (Levalbuterol Tartrate) Metered-Dose … - Mar 14, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX(R) brand levalbuterol HCl Inhalation Solution ... DG News Sepracor Presents OMNARIS(TM) HFA Nasal Aerosol Large-Scale Phase … - Mar 17, 2008 Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... Lifescience-online Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands … - Jun 3, 2008 Currently marketed products include LUNESTA ® brand eszopiclone, XOPENEX ® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA ® brand levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Announces Fourth Quarter and Full Year 2006 Results.( … - Jan 31, 2007 ...pharmaceutical product sales were approximately $348.8 million (XOPENEX([R]) brand levalbuterol HCl Inhalation Solution revenues were $179.9 million, ... $4.95 - Business Wire - ECNext Prevention of bronchospasm - FDA Approves Sepracor's XOPENEX HFA( … - Mar 13, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX(R) brand levalbuterol HCl Inhalation Solution ... Medical News Today - Medical News Today (press release) Sepracor Announces Phase III Data For Eslicarbazepine Acetate … - Jun 21, 2008 Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol ... Medical News Today - Medical News Today (press release) Sepracor takes issue with CMS "bundling" of Xopenex. - Jun 25, 2007 ...bundled, third-quarter 2007 payment amount for Xopenex (levalbuterol HCl) Inhalation Solution and generic albuterol inhalation solution products. ... $9.94 - Pharma Marketletter - Alacra Store Sepracor Inc. Reports 2007 Fourth Quarter and Full-Year Results, … - Feb 29, 2008 ...to institute a new, bundled payment amount for XOPENEX(R) brand levalbuterol HCl Inhalation Solution and generic albuterol inhalation solution products. ... Lifescience-online Sepracor gets notice of ANDA on levalbuterol. - Sep 19, 2005 ...has received an Abbreviated New Drug Application from Breath Limited for a generic version of the firm's Xopenex (levalbuterol HCl) inhalation solution. ... $4.95 - Pharma Marketletter - ECNext Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial … - May 1, 2008 Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Sepracor Announces Senior Management Appointments - Aug 19, 2008 Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Drug Delivery; FDA approves XOPENEX HFA metered-dose inhaler - Apr 11, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX brand levalbuterol HCl Inhalation Solution administered ... Pay-Per-View - Respiratory Therapeutics Week - Factiva, from Dow Jones Trudell Innovation to Benefit US Asthma Patients AEROCOUNT ® Dose … - May 7, 2008 Currently marketed products include LUNESTA ® brand eszopiclone, XOPENEX ® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA ® brand levalbuterol ... prweb.com Sepracor and Arrow Sign Global License and Development Agreement … - May 1, 2008 XOPENEX brand levalbuterol HCl Inhalation Solution is a fast-acting medicine that is used to treat the narrowing of airways (bronchospasm) caused by asthma ... Genetic Engineering News - Genetic Engineering News (press release) Drug Delivery; FDA approves XOPENEX HFA metered-dose inhaler - Apr 17, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX brand levalbuterol HCl Inhalation Solution administered ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Sepracor, Inc. FDA approves XOPENEX HFA metered-dose inhaler - Apr 13, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX brand levalbuterol HCl Inhalation Solution administered ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Press Release: FDA Approves Sepracor's XOPENEX HFA(TM) Metered- … - Mar 11, 2005 This product will also allow those patients who are currently benefiting from therapy with XOPENEX(R) brand levalbuterol HCl Inhalation Solution ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Bellwether Report is Aggressively Following Sepracor... - Oct 25, 2005 ...million ($92.5 million for sales of XOPENEX brand levalbuterol HCl Inhalation Solution and $100.9 million for sales of LUNESTA(TM) brand eszopiclone). ... Pay-Per-View - M2 Presswire - HighBeam Research Bellwether Report is Aggressively Following Sepracor Inc. - Oct 25, 2005 ...million ($92.5 million for sales of XOPENEX brand levalbuterol HCl Inhalation Solution and $100.9 million for sales of LUNESTA(TM) brand eszopiclone). ... $4.95 - M2 Presswire - ECNext Press Release: MIGENIX Corporate Update and Requisition of Special … - Jul 8, 2008 Developed and Self-Marketed Program Update XOPENEX (levalbuterol HCl ... sleep disorders. An additional Phase III study for ESTORRA is nearing completion . ... Pay-Per-View - PR Newswire - HighBeam Research BIAL LICENCIA POR PRIMERA VEZ SU ANTIEPILÉPTICO A UNA … - Jan 8, 2008 La gama de medicamentos que Sepracor comercializa actualmente incluyen LUNESTA® (eszopiclone), XOPENEX® (levalbuterol HCL) solución para inhalación, ... acceso.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |